{"denoms":[{"counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"63"}],"units":"Participants"}],"groups":[{"description":"CCI779 and Bortezomib Phase I part of this Phase I/II study.","id":"BG000","title":"CCI779 and Bortezomib Phase I"},{"description":"CCI779 and Bortezomib Phase II part of this Phase I/II study","id":"BG001","title":"CCI779 and Bortezomib Phase II"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"38"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"25"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"31"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"32"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"63"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}